Literature DB >> 23288958

Real-world challenges to the practice of evidence-based medicine.

Robert McCarthy1, John Hawboldt, Erin Davis.   

Abstract

Year:  2012        PMID： 23288958      PMCID： PMC3517794          DOI： 10.4212/cjhp.v65i6.1198

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  11 in total

1.  Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.

Authors:  Gregory S Sawicki; James E Signorovitch; Jie Zhang; Dominick Latremouille-Viau; Markus von Wartburg; Eric Q Wu; Lizheng Shi
Journal:  Pediatr Pulmonol       Date:  2011-08-03

2.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

3.  Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.

Authors:  Richard B Moss
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

4.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Authors:  Patrick A Flume; Brian P O'Sullivan; Karen A Robinson; Christopher H Goss; Peter J Mogayzel; Donna Beth Willey-Courand; Janet Bujan; Jonathan Finder; Mary Lester; Lynne Quittell; Randall Rosenblatt; Robert L Vender; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

5.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

Review 6.  Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?

Authors:  A L Smith
Journal:  J Cyst Fibros       Date:  2002-12       Impact factor: 5.482

7.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

8.  Macromolecular mechanisms of sputum inhibition of tobramycin activity.

Authors:  B E Hunt; A Weber; A Berger; B Ramsey; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.

Authors:  P M Mendelman; A L Smith; J Levy; A Weber; B Ramsey; R L Davis
Journal:  Am Rev Respir Dis       Date:  1985-10

Review 10.  Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

Authors:  Harry Heijerman; Elsbeth Westerman; Steven Conway; Daan Touw; Gerd Döring
Journal:  J Cyst Fibros       Date:  2009-06-25       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.